Tech Company Financing Transactions
Madison Vaccines Funding Round
Venture Investors joined a $1.5 million funding round for Madison Vaccines. The financing round was announced on 3/31/2016.
Transaction Overview
Company Name
Announced On
3/31/2016
Transaction Type
Venture Equity
Amount
$1,516,000
Round
Undisclosed
Investors
Venture Investors (Paul Weiss)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
505 South Rosa Rd. 201
Madison, WI 53719
USA
Madison, WI 53719
USA
Phone
Website
Email Address
Not Recorded
Overview
The principal mission of Madison, Wisconsin-based MVI is the development of therapeutic plasmid DNA vaccine products for patients with prostate cancer. MVI is also developing a sensitivity test to identify those patients who will derive clinical benefit from these vaccines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rick Lesniewski
Chief Scientific Officer
Douglas McNeel
Browse more venture capital transactions:
Prev: 3/31/2016: Blyncsy venture capital transaction
Next: 3/31/2016: Visterra venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC transactions reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs